References
- James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al.. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.
- Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol. 2011;18:105–10.
- Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, et al.. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756–61.
- Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al.. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117–27.
- Harrison CN, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V, et al.. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) vs best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol. 2011;29:Abstract LBA6501.
- Verstovsek S, Kiladjian J, Waltzman RJ, Sandor V, Lukawy J, Garrett WM, et al.. RESPONSE: a randomized, open label, phase III study of INC424 in polycythemia vera (PV) in patients resistant to or intolerant of hydroxyurea (HU). J Clin Oncol. 2011;29:Abstract TPS203.
- Pardanani AD, Caramazza D, George G, Lasho TL, Hogan WJ, Litzow MR, et al.. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol. 2011;29:Abstract 6514.
- Deeg HJ, Odenike O, Scott BL, Estrov Z, Cortes JE, Thomas DA, et al.. Phase II study of SB1518, an orally available novel JAK2 inhibitor in patients with myelofibrosis. J Clin Oncol. 2011;29:Abstract 6515.
- Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al.. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29:789–96.
- Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, et al.. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115:1131–6.